212-OR: Five-Year Follow-Up of Lipid, Inflammatory, Hepatic, and Renal Markers in People with T2 Diabetes on a Very-Low-Carbohydrate Intervention Including Nutritional Ketosis (VLCI) via Continuous Remote Care (CRC)

212-OR: Five-Year Follow-Up of Lipid, Inflammatory, Hepatic, and Renal Markers in People with T2 Diabetes on a Very-Low-Carbohydrate Intervention Including Nutritional Ketosis (VLCI) via Continuous Remote Care (CRC)

Objective: To address the long-term effectiveness of VLCI for T2D, we report changes in lipids, inflammatory, hepatic, and renal markers at 5y. Research Design and Methods: Of the 200 subjects with T2D reaching 2-years in a non-randomized, controlled trial of CRC emphasizing VLCI, 169 (84.5%) consen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2022-06, Vol.71 (Supplement_1)
Hauptverfasser: ROBERTS, CAROLINE G.P., ATHINARAYANAN, SHAMINIE J., VANTIEGHEM, MICHELLE, MCKENZIE, AMY L., VOLK, BRITTANIE M., ADAMS, REBECCA N., FELL, BRANDON, RATNER, ROBERT E., VOLEK, JEFF, PHINNEY, STEPHEN, HALLBERG, SARAH
Format: Artikel
Sprache:eng
Schlagworte:
Cholesterol
Diabetes
Diabetes mellitus
Dyslipidemia
Epidermal growth factor receptors
Inflammation
Kidneys
Lipids
Liver
Triglycerides
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective: To address the long-term effectiveness of VLCI for T2D, we report changes in lipids, inflammatory, hepatic, and renal markers at 5y. Research Design and Methods: Of the 200 subjects with T2D reaching 2-years in a non-randomized, controlled trial of CRC emphasizing VLCI, 169 (84.5%) consented to 3-year extension and 122 (61%) completed 5y. Metabolic changes from baseline (BL) to 5y were assessed with linear mixed effect models as an intent-to-treat analysis (n=169) . Holm-Bonferroni adjusted p-values are
ISSN:0012-1797
1939-327X
DOI:10.2337/db22-212-OR